MeSH Browser

MeSH Heading: Anistreplase
Tree Number(s): D08.811.277.656.300.760.635.075; D08.811.277.656.300.775.075; D08.811.277.656.959.350.635.075; D12.776.124.125.662.537.075
Unique ID: D016255
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D016255
Scope Note: An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
Entry Term(s): APSAC; Anisoylated Plasminogen-Streptokinase Activator Complex; BRL-26921; Eminase; Iminase
Pharm Action: Fibrinolytic Agents
CAS Type 1 Name: Anistreplase
Previous Indexing: Fibrinolytic Agents (1966-1990); Plasminogen (1966-1990); Streptokinase (1966-1990)
Public MeSH Note: 91
History Note: 91
Date Established: 1991/01/01
Date of Entry: 1990/05/07
Revision Date: 2016/07/01

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

analysis (AN)

antagonists & inhibitors (AI)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

deficiency (DF)

drug effects (DE)

economics (EC)

genetics (GE)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

physiology (PH)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

ultrastructure (UL)

urine (UR)

Concept UI: M0024829
Scope Note: An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.
Terms: Anistreplase Preferred Term
Term UI T048404
Date01/01/1999
LexicalTag NON
ThesaurusID; Anisoylated Plasminogen-Streptokinase Activator Complex
Term UI T048403
Date03/26/1990
LexicalTag NON
ThesaurusID NLM (1991); APSAC
Term UI T048405
Date03/26/1990
LexicalTag ABB
ThesaurusID NLM (1991)

Anistreplase MeSH Descriptor Data 2024